升高脂蛋白 (a) 和透析功能障碍之间的关联:一个回顾性队列研究
Hesham Sheashaa1, Kamal Awad1, Arshad Mohammed2
1Department of Cardiovascular Medicine, Mayo Clinic, 5777 E Mayo Blvd, Phoenix, AZ, 85054, USA.
概括
升高的脂蛋白[Lp[a]与缩功能障碍 (DD) 没有联系,这些患者有保存的喷射分数 (EF). 传统的心血管风险因素,而不是Lp (a),与DD相关.
科学领域:
- 心脏病学 心脏病学
- 心血管研究研究心血管研究
- 临床医学 临床医学
背景情况:
- 脂蛋白 (a) [Lp (a) ]涉及到心肌纤维化和内皮功能障碍,是扩张性功能障碍 (DD) 的潜在贡献者.
- 这项研究调查了Lp(a) 水平升高 (≥50 mg/dL) 和DD之间的关联,在患有保留射出分数 (EF) 的患者中.
研究的目的:
- 为了评估升高的脂蛋白 (a) 和在患有保存喷射分数的患者中扩张性功能障碍之间的关系.
- 在这个患者群体中识别与腹功能障碍相关的因素.
主要方法:
- 对1492名成年患者进行Lp(a) 测量和心声回声图的分析.
- 通过≥3个异常心声学参数定义的透析功能障碍.
- 对潜在混因素进行调整后的物流回归分析.
主要成果:
- 升高的Lp (a) (≥50 mg/dL) 没有与腹功能障碍相关 (aOR:0.89,95% CI:0.49-1.54).
- 年龄,高血压,糖尿病和先前存在的心血管疾病与DD有显著的关联.
- 静止剂治疗显示DD的风险降低 (aOR:0.51).
结论:
- 脂蛋白 (a) 不与有保存的喷射分数的患者的透缩功能障碍有关.
- 对传统的心血管风险因素的管理对于解决这种队列中透支功能障碍至关重要.
相关概念视频
Coronary Artery Disease I: Introduction
54
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
54
Atherosclerosis I: Introduction
74
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
74
Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Peripheral Artery Disease I: Introduction
32
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
32
Coronary Artery Disease II: Pathophysiology
33
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
33
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
33
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
33


